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Abstract
Reproducible science requires transparent reporting. The ARRIVE guidelines (Animal Research: Reporting of In Vivo
Experiments) were originally developed in 2010 to improve the reporting of animal research. They consist of a
checklist of information to include in publications describing in vivo experiments to enable others to scrutinise the
work adequately, evaluate its methodological rigour, and reproduce the methods and results. Despite considerable
levels of endorsement by funders and journals over the years, adherence to the guidelines has been inconsistent,
and the anticipated improvements in the quality of reporting in animal research publications have not been
achieved. Here, we introduce ARRIVE 2.0. The guidelines have been updated and information reorganised to
facilitate their use in practice. We used a Delphi exercise to prioritise and divide the items of the guidelines into 2
sets, the “ARRIVE Essential 10,” which constitutes the minimum requirement, and the “Recommended Set,” which
describes the research context. This division facilitates improved reporting of animal research by supporting a
stepwise approach to implementation. This helps journal editors and reviewers verify that the most important items
are being reported in manuscripts. We have also developed the accompanying Explanation and Elaboration
document, which serves (1) to explain the rationale behind each item in the guidelines, (2) to clarify key concepts,
and (3) to provide illustrative examples. We aim, through these changes, to help ensure that researchers, reviewers,
and journal editors are better equipped to improve the rigour and transparency of the scientific process and thus
reproducibility.
Why good reporting is important
In recent years, concerns about the reproducibility of
research findings have been raised by scientists, funders,
research users, and policy makers [1, 2]. Factors that
contribute to poor reproducibility include flawed study
design and analysis, variability and inadequate validation
of reagents and other biological materials, insufficient
reporting of methodology and results, and barriers to
accessing data [3]. The bioscience community has
introduced a range of initiatives to address the problem,
from open access and open practices to enable the
scrutiny of all aspects of the research [4, 5] through to
study preregistration to shift the focus towards robust
methods rather than the novelty of the results [6, 7], as
well as resources to improve experimental design and
statistical analysis [8–10].
Transparent reporting of research methods and find-
ings is an essential component of reproducibility. With-
out this, the methodological rigour of the studies cannot
be adequately scrutinised, the reliability of the findings
cannot be assessed, and the work cannot be repeated or
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built upon by others. Despite the development of
specific reporting guidelines for preclinical and clinical
research, evidence suggests that scientific publications
often lack key information and that there continues to
be considerable scope for improvement [11–18]. Animal
research is a good case in point, where poor reporting
impacts on the development of therapeutics and irrepro-
ducible findings can spawn an entire field of research, or
trigger clinical studies, subjecting patients to interven-
tions unlikely to be effective [2, 19, 20].
In an attempt to improve the reporting of animal
research, the ARRIVE guidelines (Animal Research:
Reporting of In Vivo Experiments) were published in
2010. The guidelines consist of a checklist of the items
that should be included in any manuscript that reports
in vivo experiments, to ensure a comprehensive and
transparent description [21–30]. They apply to any area
of research using live animal species and are especially
pertinent to describe comparative research in the labora-
tory or other formal test setting. The guidelines are also
relevant in a wider context, for example, for observa-
tional research, studies conducted in the field, and where
animal tissues are used. In the 10 years since publication,
the ARRIVE guidelines have been endorsed by more
than a thousand journals from across the life sciences.
Endorsement typically includes advocating their use in
guidance to authors and reviewers. However, despite this
level of support, recent studies have shown that import-
ant information as set out in the ARRIVE guidelines is
still missing from most publications sampled. This
includes details on randomisation (reported in only 30–
40% of publications), blinding (reported in only approxi-
mately 20% of publications), sample size justification
(reported in less than 10% of publications), and animal
characteristics (all basic characteristics reported in less
than 10% of publications) [11, 31, 32].
Evidence suggests that 2 main factors limit the impact of
the ARRIVE guidelines. The first is the extent to which edi-
torial and journal staff are actively involved in enforcing
reporting standards. This is illustrated by a randomised
controlled trial at PLOS ONE, designed to test the effect of
requesting a completed ARRIVE checklist in the manu-
script submission process. This single editorial intervention,
which did not include further verification from journal staff,
failed to improve the disclosure of information in published
papers [33]. In contrast, other studies using shorter check-
lists (primarily focused on experimental design) with more
editorial follow-up have shown a marked improvement in
the nature and detail of the information included in publi-
cations [34–36]. It is likely that the level of resource
required from journals and editors currently prohibits the
implementation of all the items of the ARRIVE guidelines.
The second issue is that researchers and other individ-
uals and organisations responsible for the integrity of
the research process are not sufficiently aware of the
consequences of incomplete reporting. There is some
evidence that awareness of ARRIVE is linked to the use
of more rigorous experimental design standards [37];
however, researchers are often unfamiliar with the much
larger systemic bias in the publication of research and in
the reliability of certain findings and even of entire fields
[33, 38–40]. This lack of understanding affects how
experiments are designed and grant proposals prepared,
how animals are used and data recorded in the labora-
tory, and how manuscripts are written by authors or
assessed by journal staff, editors, and reviewers.
Approval for experiments involving animals is gener-
ally based on a harm–benefit analysis, weighing the
harms to the animals involved against the benefits of the
research to society. If the research is not reported in
enough detail, even when conducted rigorously, the
benefits may not be realised, and the harm–benefit
analysis and public trust in the research are undermined
[41]. As a community, we must do better to ensure that,
where animals are used, the research is both well
designed and analysed as well as transparently reported.
Here, we introduce the revised ARRIVE guidelines,
referred to as ARRIVE 2.0. The information included
has been updated, extended, and reorganised to facilitate
the use of the guidelines, helping to ensure that
researchers, editors, and reviewers—as well as other
relevant journal staff—are better equipped to improve
the rigour and reproducibility of animal research.
Introducing ARRIVE 2.0
In ARRIVE 2.0, we have improved the clarity of the
guidelines, prioritised the items, added new information,
and generated the accompanying Explanation and Elab-
oration (E&E) document to provide context and ration-
ale for each item [42] (also available at https://www.
arriveguidelines.org). New additions comprise inclusion
and exclusion criteria, which are a key aspect of data
handling and prevent the ad hoc exclusion of data [43];
protocol registration, a recently emerged approach that
promotes scientific rigour and encourages researchers to
carefully consider the experimental design and analysis
plan before any data are collected [44]; and data access,
in line with the FAIR Data Principles (Findable, Access-
ible, Interoperable, Reusable) [45]. Additional file 1 sum-
marises the changes.
The most significant departure from the original
guidelines is the classification of items into 2 prioritised
groups, as shown in Tables 1 and 2. There is no ranking
of the items within each group. The first group is the
“ARRIVE Essential 10,” which describes information that
is the basic minimum to include in a manuscript, as
without this information, reviewers and readers cannot
confidently assess the reliability of the findings
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presented. It includes details on the study design, the
sample size, measures to reduce subjective bias, outcome
measures, statistical methods, the animals, experimental
procedures, and results. The second group, referred to
as the “Recommended Set,” adds context to the study
described. This includes the ethical statement, declar-
ation of interest, protocol registration, and data access,
as well as more detailed information on the methodology
such as animal housing, husbandry, care, and monitoring.
Items on the abstract, background, objectives, interpret-
ation, and generalisability also describe what to include in
the more narrative parts of a manuscript.
Revising the guidelines has been an extensive and
collaborative effort, with input from the scientific com-
munity carefully built into the process. The revision of
the ARRIVE guidelines has been undertaken by an inter-
national working group—the authors of this publica-
tion—with expertise from across the life sciences
community, including funders, journal editors, statisti-
cians, methodologists, and researchers from academia
and industry. We used a Delphi exercise [46] with exter-
nal stakeholders to maximise diversity in fields of expert-
ise and geographical location, with experts from 19
countries providing feedback on each item, suggesting
new items, and ranking items according to their relative
importance for assessing the reliability of research find-
ings. This ranking resulted in the prioritisation of the
items of the guidelines into the 2 sets. Demographics of
the Delphi panel and full methods and results are
presented in Additional files 2 and 3. Following their
publication on BioRxiv, the revised guidelines and the
E&E were also road tested with researchers preparing
manuscripts describing in vivo studies, to ensure that
Table 1 ARRIVE Essential 10
ARRIVE Essential 10
Study design 1 For each experiment, provide brief details of
study design including:
a. The groups being compared, including
control groups. If no control group has been
used, the rationale should be stated.
b. The experimental unit (e.g., a single animal,
litter, or cage of animals).
Sample size 2 a. Specify the exact number of experimental
units allocated to each group, and the total
number in each experiment. Also indicate
the total number of animals used.
b. Explain how the sample size was decided.
Provide details of any a priori sample size
calculation, if done.
Inclusion and
exclusion criteria
3 a. Describe any criteria used for including
and excluding animals (or experimental units)
during the experiment, and data points
during the analysis. Specify if these criteria
were established a priori. If no criteria were
set, state this explicitly.
b. For each experimental group, report any
animals, experimental units, or data points
not included in the analysis and explain why.
If there were no exclusions, state so.
c. For each analysis, report the exact value
of n in each experimental group.
Randomisation 4 a. State whether randomisation was used to
allocate experimental units to control and
treatment groups. If done, provide the
method used to generate the randomisation
sequence.
b. Describe the strategy used to minimise
potential confounders such as the order of
treatments and measurements, or
animal/cage location. If confounders were
not controlled, state this explicitly.
Blinding 5 Describe who was aware of the group
allocation at the different stages of the
experiment (during the allocation, the
conduct of the experiment, the outcome
assessment, and the data analysis).
Outcome measures 6 a. Clearly define all outcome measures
assessed (e.g., cell death, molecular markers,
or behavioural changes).
b. For hypothesis-testing studies, specify the
primary outcome measure, i.e., the outcome
measure that was used to determine the
sample size.
Statistical methods 7 a. Provide details of the statistical methods
used for each analysis, including software
used.
b. Describe any methods used to assess
whether the data met the assumptions of
the statistical approach, and what was done
if the assumptions were not met.
Experimental
animals
8 a. Provide species-appropriate details of the
animals used, including species, strain and
substrain, sex, age or developmental stage,
and, if relevant, weight.
b. Provide further relevant information on the
provenance of animals, health/immune status,
genetic modification status, genotype, and
any previous procedures.
Table 1 ARRIVE Essential 10 (Continued)
ARRIVE Essential 10
Experimental
procedures
9 For each experimental group, including
controls, describe the procedures in enough
detail to allow others to replicate them,
including:
a. What was done, how it was done, and
what was used.
b. When and how often.
c. Where (including detail of any
acclimatisation periods).
d. Why (provide rationale for procedures).
Results 10 For each experiment conducted, including
independent replications, report:
a. Summary/descriptive statistics for each
experimental group, with a measure of
variability where applicable (e.g., mean
and SD, or median and range).
b. If applicable, the effect size with a
confidence interval.
Explanations and examples for items 1 to 10 are available in the Explanation
and Elaboration document [42] and on the website
at https://www.arriveguidelines.org).
Abbreviations: ARRIVE guidelines (Animal Research: Reporting of In
Vivo Experiments)
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these documents were well understood and useful to the
intended users. This study is presented in Additional
files 4 and 5.
While reporting animal research in adherence to all
21 items of ARRIVE 2.0 represents best practice, the
classification of the items into 2 groups is intended to
facilitate the improved reporting of animal research
by allowing an initial focus on the most critical is-
sues. This better allows journal staff, editors, and re-
viewers to verify that the items have been adequately
reported in manuscripts. The first step should be to
ensure compliance with the ARRIVE Essential 10 as a
minimum requirement. Items from the Recommended
Set can then be added over time and in line with spe-
cific editorial policies until all the items are routinely
reported in all manuscripts. ARRIVE 2.0 are fully
compatible with and complementary to other guide-
lines that have been published in recent years. By
providing a comprehensive set of recommendations
that are specifically tailored to the description of
in vivo research, they help authors reporting animal
experiments adhere to the National Institutes of
Health (NIH) standards [43] and the minimum stan-
dards framework and checklist (Materials, Design, Ana-
lysis and Reporting [MDAR] [47]). The revised guidelines
are also in line with many journals’ policies and will assist
authors in complying with information requirements on
the ethical review of the research [48, 49], data presentation
and access [50–52], statistical methods [51, 52], and con-
flicts of interest [53, 54].
Although the guidelines are written with researchers
and journal editorial policies in mind, it is important to
stress that researchers alone should not have to carry
the responsibility for transparent reporting. Funders,
institutions, and publishers’ endorsement of ARRIVE has
been instrumental in raising awareness to date; they now
have a key role to play in building capacity and cham-
pioning the behavioural changes required to improve
reporting practices. This includes embedding ARRIVE
2.0 in appropriate training, workflows, and processes to
support researchers in their different roles. While the
primary focus of the guidelines has been on the report-
ing of animal studies, ARRIVE also has other applica-
tions earlier in the research process, including in the
planning and design of in vivo experiments. For
example, requesting a description of the study design in
line with the guidelines in funding or ethical review
applications ensures that steps to minimise experimental
bias are considered at the beginning of the research
cycle [55].
Conclusion
Transparent reporting is clearly essential if animal stud-
ies are to add to the knowledge base and inform future
Table 2 ARRIVE Recommended Set
Recommended Set
Abstract 11 Provide an accurate summary of the research
objectives, animal species, strain and sex, key
methods, principal findings, and study
conclusions.
Background 12 a. Include sufficient scientific background to
understand the rationale and context for the
study, and explain the experimental approach.
b. Explain how the animal species and model
used address the scientific objectives and, where
appropriate, the relevance to human biology.
Objectives 13 Clearly describe the research question, research
objectives and, where appropriate, specific
hypotheses being tested.
Ethical statement 14 Provide the name of the ethical review
committee or equivalent that has approved the
use of animals in this study, and any relevant
licence or protocol numbers (if applicable). If
ethical approval was not sought or granted,
provide a justification.
Housing and
husbandry
15 Provide details of housing and husbandry
conditions, including any environmental
enrichment.
Animal care and
monitoring
16 a. Describe any interventions or steps taken in
the experimental protocols to reduce pain,
suffering, and distress.
b. Report any expected or unexpected adverse
events.
c. Describe the humane endpoints established
for the study, the signs that were monitored,
and the frequency of monitoring. If the study
did not have humane endpoints, state this.
Interpretation/
scientific implications
17 a. Interpret the results, taking into account the
study objectives and hypotheses, current theory,
and other relevant studies in the literature.
b. Comment on the study limitations, including
potential sources of bias, limitations of the
animal model, and imprecision associated with
the results.
Generalisability/
translation
18 Comment on whether, and how, the findings of
this study are likely to generalise to other
species or experimental conditions, including
any relevance to human biology (where
appropriate).
Protocol registration 19 Provide a statement indicating whether a
protocol (including the research question, key
design features, and analysis plan) was prepared
before the study, and if and where this protocol
was registered.
Data access 20 Provide a statement describing if and where
study data are available.
Declaration of
interests
21 a. Declare any potential conflicts of interest,
including financial and nonfinancial. If none
exist, this should be stated.
b. List all funding sources (including grant
identifier) and the role of the funder(s) in the
design, analysis, and reporting of the study.
Together with the Essential 10, the Recommended Set represents best
reporting practice. Explanations and examples for items 11 to 21 are
available in the Explanation and Elaboration document [42] and on the
website https://www.arriveguidelines.org.
Abbreviations: ARRIVE guidelines (Animal Research: Reporting of In
Vivo Experiments)
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research, policy, and clinical practice. ARRIVE 2.0 priori-
tises the reporting of information related to study reli-
ability. This enables research users to assess how much
weight to ascribe to the findings and, in parallel, pro-
motes the use of rigorous methodology in the planning
and conduct of in vivo experiments [37], thus increasing
the likelihood that the findings are reliable and, ultim-
ately, reproducible.
The intention of ARRIVE 2.0 is not to supersede indi-
vidual journal requirements but to promote a harmonised
approach across journals to ensure that all manuscripts
contain the essential information needed to appraise the
research. Journals usually share a common objective of
improving the methodological rigour and reproducibility
of the research they publish, but different journals empha-
sise different pieces of information [56–58]. Here, we
propose an expert consensus on information to prioritise.
This will provide clarity for authors, facilitate transfer of
manuscripts between journals, and accelerate an improve-
ment of reporting standards.
Concentrating the efforts of the research and publish-
ing communities on the ARRIVE Essential 10 items pro-
vides a manageable approach to evaluate reporting
quality efficiently and assess the effect of interventions
and policies designed to improve the reporting of animal
experiments. It provides a starting point for the develop-
ment of operationalised checklists to assess reporting,
ultimately leading to the build of automated or semi-
automated artificial intelligence tools that can detect
missing information rapidly [59].
Improving reporting is a collaborative endeavour, and
concerted effort from the biomedical research commu-
nity is required to ensure maximum impact. We wel-
come collaboration with other groups operating in this
area, as well as feedback on ARRIVE 2.0 and our imple-
mentation strategy.
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